Drug intelligence / Profile preview

Novel Compound 8

Development stage: Preclinical
Lead developer: Eluciderm
Modality: Small Molecules
Administration: Topical

Overview

Novel Compound 8, also known as the adenylate of THK, is a small molecule therapeutic candidate currently in preclinical development by Eluciderm. It is being investigated for the topical treatment of colorectal cancer. Eluciderm's broader research platform focuses on the modulation of the Wnt signaling pathway to stimulate regenerative processes, although the specific molecular target of Novel Compound 8 has not been publicly disclosed. The use of a topical route for colorectal cancer suggests a specialized delivery approach or focus on specific disease manifestations.

Other names: adenylate of THK

Beyond the preview

Go deeper on Novel Compound 8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel Compound 8.

Explore the full profile